ISSUE 84 I JULY 2019

the deep dive

for new drugs

Could the underwater biome become natures’
next drug treasure trove? 

NASH: inside the race to market

The promise of proteomics 

Predicting drug failures with AI

In association  with

02/24/2024 17:59:09
  • Home | The deep dive for new drugs
  • In this issue
  • NSF
  • Contents
  • Hapa Company Insight
  • Daiichi Jitsugyo
  • News
  • Owen Mumford
  • The pharma industry briefing
  • Capsugel Company Insight
  • Swiss WorldCargo
  • In the age of AMR, does a nationalised drug company make sense? The case for and against
  • Accurate Biometrics Company Insight
  • Accurate Biometrics
  • Underwater forests and the search for natures’ next drug treasure trove
  • Barc Lab
  • BEA
  • Developing drugs for NASH: the race to market
  • SmartCAE Company Insight
  • SmartCAE
  • Zulresso: the world’s first post-partum depression drug
  • Ecocool
  • Moehs Iberica SL
  • Predicting drug flops with AI
  • Abiogen Pharma
  • Lauda
  • Proteomics and the promise of ‘enriching’ clinical trials
  • Lubrizol Life Sciences
  • Skycell
  • Events
  • Temptime
  • Next issue
  • Pfanstiehl Company Insight
  • Pfanstiehl
06/20/2019 00:00:00